In a pilot project, Optima Pharma and Charité – Universitätsmedizin Berlin are developing a production platform for the automatic manufacturing and filling of cell and gene therapeutics. These new types of medicine are paving the way for personalized medicine and are considered a promising new therapy possibility for hereditary and metabolic diseases, neurodegenerative disorders, and cancer. These medications depend on the patient’s cells and are still produced manually, for each individual patient, which is very expensive. The new project is financed by the Berlin Institute of Health (BIH).